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COST OF ILLNESS
TPIL1
ANALYSIS OF DIRECT, INDIRECT, AND
TOTAL COSTS OF ASTHMA FROM PATIENT 
SURVEY DATA
Johnson KA, Ernst RL, Ogostalick AE
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: This study estimated the direct, indirect, and
total costs of asthma and evaluated the impact of symp-
tom severity, disease control, and the National Asthma
Education and Prevention Program treatment guidelines
on cost of asthma care using patient survey data.
METHODS: Data were obtained from a 1993 US house-
hold survey to determine the costs of asthma (N  698).
Costs were developed by assigning unit costs to reported
medical utilization and unpaid resource usage and were
reported in 1994 US dollars. A multivariate regression
model was developed to determine factors associated with
higher asthma costs.
RESULTS: The average annual total cost of asthma care
was US$966 per person, ranging from US$47 (controlled
symptoms) to US$7030 (uncontrolled symptoms). Costs
for uncontrolled patients were due mainly to costs of
hospitalization and indirect costs of missed days from
work. Based on the reported incidence of asthma in the
United States, the cost of asthma care is estimated at
US$9.6 billion. Significant predictors of higher direct, indi-
rect, and total costs of asthma include symptom severity (p
 0.001) and following pharmacotherapy guidelines (p 
0.01). Younger age is associated with higher costs in the
indirect and total cost models (p  0.01 and p  0.05).
Smoking is associated with higher indirect costs (p 
0.05). Lower total and direct costs are associated with pa-
tients who self-pay for healthcare (p  0.05). Lower indi-
rect costs are associated with patients who report their
asthma is controlled (p  0.05).
CONCLUSION: Symptom severity is associated with
higher asthma care costs. Our findings suggest that either
people not meeting guidelines also have zero medical ex-
penses or adherence to the treatment guidelines actually
increases costs. A prospective study is necessary to deter-
mine the impact of guidelines.
TPIL2
THE COST OF TREATING PARKINSON’S 
DISEASE (PD) IN THE CALIFORNIA MEDICAID 
(MEDI-CAL) PROGRAM
McCombs JS, Nichol MB, Lyu RR, Shi L
Department of Pharmaceutical Economics & Policy, University 
of Southern California, Los Angeles, CA, USA
OBJECTIVE: A critical factor used by healthcare organi-
zations in evaluating new medications is baseline data on
current costs of treating the disease in question. This
study investigated the healthcare use and cost patterns
for PD patients in the Medi-Cal program.
METHODS: The data for the analysis were derived from
the paid claims data of Medi-Cal program from January
1987 to July 1996. Up to 4 years of episodic anti-PD drug
use patterns and associated direct healthcare costs were
abstracted for each patient. Descriptive statistics and mul-
tivariate OLS models were employed in the study.
RESULTS: Although a significant proportion of PD pa-
tients did not use any anti-PD regimen during the first
year (23.4% of institutionalized patients, 17.5% of com-
munity-based patients), anti-PD drug use was negatively
correlated with total first-year healthcare costs (yet not
significant) in both groups. Significant association was
found between prior hospitalization and healthcare costs
(P  0.0001). No statistically significant differences were
found across alternative anti-PD medications when used
as initial therapy for both community-based and institu-
tionalized patients. Healthcare expenditures of commu-
nity-based patients increased from approximately $11,000
per patient for the first treatment year to over $27,000 per
patient-year by the end of 4 years. Annual costs for insti-
tutionalized patients in the first year exceeded $85,000
per patient-year and decreased slightly over 4 years.
Compliance rate in community-based PD patients was
significantly lower than that of institutionalized patients
(25% versus 57%, p  0.001).
CONCLUSIONS: Anti-PD drug therapy might have po-
tential cost saving effect on first-year healthcare services.
Prior use of hospital service was a significant predictor of
overall direct healthcare costs of PD patients in the Medi-
Cal program.
TPIL3
THE MEDICAL COST OF OSTEOARTHRITIS
AND RHEUMATOID ARTHRITIS: METHODS
AND EVIDENCE
Lee DW2, Meyer J1, Clouse J1
1Ingenix, Eden Prairie, MN, USA; 2GD Searle, Skokie, IL, USA
OBJECTIVE: To evaluate the impact of controlling and
not controlling for comorbid conditions on the estimated
cost of osteoarthritis (OA) and rheumatoid arthritis (RA)
in a managed care setting.
METHODS: Medical claims data from 1996 were ob-
tained for inpatient, outpatient and pharmacy services
for members in five United Health–affiliated health plans
(enrollment: 884,000). Total costs for arthritis patients
( 1 claims with an arthritis diagnosis and  30 days of
continuous enrollment) were compared to costs among
an equal number of comparison members who were se-
lected at random after stratification by health plan, gen-
der, age category, and Medicare status. Multivariate re-
gression analysis was used to compare the natural log of
costs between the two groups under three alternative
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controls for comorbid conditions—no controls, controls
for all conditions, and controls for conditions thought to
be unrelated to arthritis.
RESULTS: In the study 5920 OA and 1310 RA patients
were identified. OA patients cost between 1.50 and 2.56
times more than non-arthritis patients, while RA patients
cost between 2.21 and 3.07 times more than non-arthritis
patients. Based on assumptions about the relationships be-
tween comorbid conditions and arthritis, our point esti-
mate is that OA adds $80 per-patient-per-month (PPPM)
compared to non-arthritis patients, while RA adds $109
PPPM compared to non-arthritis patients.
CONCLUSIONS: Arthritis increases the costs of care sig-
nificantly. Existing estimation approaches either underes-
timate the cost of arthritis by including the cost of all co-
morbid conditions, or overestimate the cost by excluding
the cost of all comorbid conditions. Our approach, which
controls for only those comorbid conditions which are
unrelated to arthritis, yields a cost estimate that falls be-
tween those estimated by existing approaches and is be-
lieved to be more precise.
TPIL4
SCHIZOPHRENIA CARE ASSESSMENT 
PROGRAM (SCAP): INITIAL FINDINGS 
ON HEALTHCARE RESOURCE UTILIZATION
IN AUSTRALIA
Gibson J, Hristova L, Davey P, Montgomery B, Kulkani J, 
de Castella A
M-TAG, Chatswood, New South Wales, Australia
OBJECTIVES: The primary aims of SCAP in Australia
are to: contribute to the establishment of a schizophrenia
outcomes database; evaluate which model of healthcare
results in better clinical outcomes and quality of life in a
naturalistic setting; and evaluate the cost of healthcare
for patients with schizophrenia. Emphasis is given to
measuring the utilization of mental healthcare services.
METHODS: SCAP is a prospective, naturalistic, non-ran-
domized 3-year follow-up study of 350 patients, with a
diagnosis of schizophrenia, schizoaffective disorder, or
schizophreniform disorder. Data on utilization of health-
care resources and costs involved in the treatment of
schizophrenia will be obtained from patient records and
from a number of state and federal databases. These cover
all healthcare services used: in hospital and out of hospi-
tal; medications and community services. The initial find-
ings based on 6-month data for the first 50 subjects were
used for a pilot study.
RESULTS: The average direct medical care cost of treating
patients over the period was calculated at A$5500. Hospi-
talizations accounted for 85% of the costs. Medications
used while the patient was in the community care ac-
counted for only 2.5% of the total costs. Ten percent of
the patients utilized over 30% of the treatment resources.
CONCLUSIONS: A full clinical costing could be under-
taken by linking data from a range of payments and activ-
ity data sets in Australia. SCAP will provide unique data
on the social and economic cost of schizophrenia. SCAP is
unique because it provides the opportunity to simulta-
neously explore a broad range of schizophrenia research
questions in a variety of settings across time. Further the
SCAP results will be drawn from a naturalistic setting and
this will enhance the generalizability of the results.
TPIL5
EVALUATION OF MEDICAL RESOURCE 
UTILIZATION IN ALZHEIMER’S DISEASE
Morris LS, Lichtenstein M, Smith J
IMS HEALTH, Plymouth Meeting, PA, USA
OBJECTIVES: Alzheimer’s disease is a growing concern
due to aging of the US population and the medical re-
sources that are consumed by these patients. This study
evaluated the changes in resource utilization for newly di-
agnosed Alzheimer’s patients and a control group.
METHODS: Using an employer claims database, pa-
tients newly diagnosed with Alzheimer’s (ICD-9-CM
331.0) in 1996 (N  265) and not previously treated
with donepezil or tacrine were followed for 12 months
preceding and following diagnosis to determine medical
resource utilization. An age and gender matched control
group was constructed. Patients were 70 years of age or
older and were required to be continuously enrolled for a
24-month period.
RESULTS: Average charges per patient for the test group
were $8292 prior to diagnosis and $14,620 following
diagnosis. The control group had average charges per pa-
tient of $6199 in the pre-period and $7232 in the post
period. Charges for drugs of interest, ER visits, inpatient
hospitalizations, labs, nursing homes, outpatient services,
and other medical resources were broken down. In the
test group following diagnosis, there was a 170% in-
crease in the charge per patient for nursing home charges.
Nursing home charges for the test group following diag-
nosis accounted for 23.5% of the overall average
charges. In the control group, nursing home charges ac-
counted for only 5% of the overall average charges.
There were also increases in charges for ER visits, inpa-
tient hospitalizations, and outpatient services for the test
group following diagnosis.
CONCLUSIONS: Patients newly diagnosed with Alzhe-
imer’s consume more medical resources, mostly through
inpatient, ER, and nursing home services. Identification
of improved therapies aimed at keeping patients out of
nursing homes could produce significant cost savings.
TPIL6
ESTIMATING THE ECONOMIC IMPACT (EI) OF 
VIRAL MENINGITIS (VM) IN THE UNITED 
STATES (US)
Parasuraman TV1, Deverka PA2, Toscani MR1 (on behalf of 
the Meningitis Consensus Panel*)
